Photoimmunotherapy for head and neck cancer: A systematic review

IF 1.6 4区医学 Q2 OTORHINOLARYNGOLOGY

Auris Nasus Larynx Pub Date : 2025-02-13 DOI:10.1016/j.anl.2025.01.005

Isaku Okamoto

引用次数: 0

Abstract

Photoimmunotherapy is a new cancer treatment that uses cetuximab sarotalocan sodium, a conjugate of cetuximab and the light activatable dye, IR700, and red light at a wavelength of 690 nm.

In Japan, photoimmunotherapy for “unresectable locally advanced or locally recurrent head and neck cancer” has been covered by insurance since 2021. Although presently approved only for head and neck cancer, photoimmunotherapy is an important technology in the future of various cancer treatments. Photoimmunotherapy is an important technology for the future of various cancer treatments, and it is essential to strive for the development and widespread use of photoimmunotherapy in clinical practice.

In this review, we will explain the mechanism of photoimmunotherapy, treatment cases, clinical trial data, reports from real world data in Japan, and future issues and prospects as seen in actual clinical practice.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Auris Nasus Larynx 医学-耳鼻喉科学

CiteScore

3.40

自引率

5.90%

发文量

169

审稿时长

30 days

期刊介绍： The international journal Auris Nasus Larynx provides the opportunity for rapid, carefully reviewed publications concerning the fundamental and clinical aspects of otorhinolaryngology and related fields. This includes otology, neurotology, bronchoesophagology, laryngology, rhinology, allergology, head and neck medicine and oncologic surgery, maxillofacial and plastic surgery, audiology, speech science. Original papers, short communications and original case reports can be submitted. Reviews on recent developments are invited regularly and Letters to the Editor commenting on papers or any aspect of Auris Nasus Larynx are welcomed. Founded in 1973 and previously published by the Society for Promotion of International Otorhinolaryngology, the journal is now the official English-language journal of the Oto-Rhino-Laryngological Society of Japan, Inc. The aim of its new international Editorial Board is to make Auris Nasus Larynx an international forum for high quality research and clinical sciences.